Ovid

Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction in seizures

All patients that have completed the Phase 2 ARCADE study to date have opted to enroll in the ENDYMION open-label extension study

In the Dup15q cohort (n=6), patients also exhibited a variety of seizures types including motor (tonic and atonic), myoclonic and absence seizures.

In one patient with pure motor seizures (34.8 seizures per 28-day baseline), seizure frequency was reduced by 90% during the 12-week maintenance phase (89% over the full treatment period). This patient also had two 28-day seizure-free periods.

The other five patients in the Dup15q cohort with mixed seizure types showed preliminary signs of efficacy, as follows:

° Three patients with myoclonic seizures showed a 60%, 66% and 100% reduction over the maintenance period (and by 74%, 65% and 100% respectively over the full treatment period).

° Two patients had absence seizures and showed a 78% and 74% reduction in absence seizures during the maintenance phase (74% and 51% reduction over the full treatment period). In the five patients that completed the full treatment period at the time of this data cut, motor seizure free days in four of these patients increased by 64%, 159%, 539% and 590%, the fifth patient did not show improvement.

Phase 2 ARCADE Study – Initial Safety Results

Soticlestat was generally well-tolerated in this study and demonstrated a safety profile consistent with the findings of previous studies. The most common adverse events were constipation (n=3; 27%), fatigue (n=2; 18%), nasopharyngitis (n=2; 18%) and seizure (n=2; 18%). Additionally, there were no adverse event-related withdrawals, serious adverse events or deaths reported.

Read More

Related Posts

November 15th – International 15q Day

November 15th – International 15q Day

November 15th - International 15q Day Together with Angelman Syndrome Foundation and the Foundation for Prader-Willi Research, we are raising awareness of the similarities between Dup15q Syndrome, Angelman and Prader-Willi Syndromes. Prader-Willi, Angelman and Dup15q...

2020 – Rare Champion of Hope Award Nominee

2020 – Rare Champion of Hope Award Nominee

Congratulations to Vanessa Vogel-Farley who has been nominated for the Global Genes 2020 Rare Champion of Hope Awards. These individuals, organizations and collaborations are the groundbreakers, leaders and advocates who inspire and catalyze change in rare disease....

  In 2020 we have worked hard on developing and expanding committees and programs that will help provide guidance and resources for families affected by Dup15q Syndrome. As we turn the corner into 2021, we are expanding our research and the search for targeted...